ClinicalTrials.gg
Status unknownNCT02323620RACE-STEMIUpdated Jan 23, 2019

Impact of Intracoronary Injection of Autologous BMMC for LV Contractility and Remodeling in Patients With STEMI

A Phase 3 interventional study of Intracoronary infusion of BM-MC in Heart Failure and Myocardial Infarction, sponsored by American Heart of Poland. Status unknown at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-23.

Sponsored by American Heart of Poland · Phase 3, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Dec 2018), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 275 studies in Heart Failure with a site in Poland — 56 open to participants now, 75 under way, 20 of them phase 3. Heart Failure · Poland.

Planned enrollment
128th of 225
200 · median 300
Started
2019
with 12 others
Phase 3
68 of 275
15 open now
Registered
89th of 275
by date

Among the 275 studies in Heart Failure with a site in Poland, this one is the 128th largest by planned enrollment of the 225 interventional ones that give a count, is one of 13 that started in 2019, is one of 68 in phase 3, and was the 89th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

56 of the 275 studies in Heart Failure with a site in Poland are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 275 studies in Heart Failure with a site in Poland, or all of them as a file.
02

Study summary

This is multicentre, randomised open-label, controlled, parallel-group phase III study. Its aim is to demonstrate that a triple intracoronary infusion of autologous bone marrow-derived mononuclear cells in addition to state of the art treatment is safe and reduces all-cause mortality in patients with reduced left ventricular ejection fraction (≤45%) after successful reperfusion for acute myocardial infarction when compared to a control group of patients undergoing best medical care.

Read the detailed description

The study is divided into 3 parts:

  • Screening phase: Patients will be recruited at the investigational clinical centers. Alternatively, patients who had primary PCI performed at institutions different from the investigational sites can also be enrolled. Interested patients may be referred for screening to any of the participating study sites after acute reperfusion therapy. Informed consent and assessment of eligibility of patients with respect to in- and exclusion criteria will be done at the investigational site. If all other eligibility criteria are met, echocardiography will be performed 3 to 6 days after the acute PCI, and ejection fraction will be quantified by a central Echo Core Lab after web based transmission. CT examination will be performed 1 month after acute PCI in all screened patients with LVEF ≤ 45%. If LVEF will not improve ≥5% in the CT the patient may be qualified into the Study.
  • Treatment phase: Bone marrow aspiration will be performed for the patients assigned to the treatment group (II). Bone marrow will be collected from the patient and MNC isolated using point-of-care system (Harvest) at a Site. Intracoronary infusion of BM-MNCs will be performed up to 2 hours after isolation via radial approach. Same procedure will be performed 3 and 6 months after first application.
  • Follow-up phase: After hospital discharge, patients will be followed up per telephone 30 days and 3, 6, 9 months after randomisation and with a site visit with CT examination 12 months after randomisation. Afterwards, telephone follow up will be performed every 3 months. Once the required number of clinical events has been observed, all patients will attend a final study visit, but minimum follow up period for each patient is 2 years. Endpoints will be reported as occurring throughout the follow up.
03

Conditions studied

  • Heart Failure
  • Myocardial Infarction

Keywords

  • Acute myocardial Infarction
  • bone marrow
  • stem cells
  • cardiovascular disease
  • mortality
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women of any ethnic origin aged ≥ 18 years.
  2. Patients with acute ST-elevation myocardial infarction as defined by the universal definition of AMI.
  3. Successful acute reperfusion therapy (residual stenosis visually \<50% and TIMI flow ≥2) within 24 hours of symptom onset or thrombolysis within 12 hours of symptom onset followed by successful percutaneous coronary intervention (PCI) within 24 hours after thrombolysis.
  4. ≤ 45% with significant regional wall motion abnormality assessed by quantitative echocardiography (central, independent core lab analysis) 3 to 6 days after reperfusion therapy
  5. Open coronary artery suitable for cell infusion supplying the target area of abnormal wall motion
  6. LVEF≤45% with significant regional wall motion abnormality assessed by computed tomography (CT) 30 days after reperfusion therapy with no LVEF improvement ≥5%.

Exclusion criteria

Exclusion Criteria:

  1. Participation in another clinical trial within 30 days prior to randomisation
  2. Previously received stem/progenitor cell therapy
  3. Pregnant or nursing women
  4. Mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study or to follow the protocol
  5. Necessity to revascularise additional vessels, outside the target coronary artery at the time of BM-MNC infusion (additional revascularisations after primary PCI and before BM-MNC cell infusion are allowed)
  6. Cardiogenic shock requiring mechanical support
  7. count \<100,000/μl, or \<8.5 g/dl
  8. Impaired renal function, i.e. serum creatinine >2.5 mg/dl
  9. Persistent fever or diarrhea not responsive to treatment within 4 weeks prior screening
  10. bleeding within 3 months prior screening
  11. Uncontrolled hypertension (systolic >180 mmHg and diastolic >120 mmHg)
  12. of less than 2 years from any non-cardiac cause or neoplastic disease
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • No intervention
    Standard care

    Optimal standard care after myocardial infarction.

  • Experimental
    Intracoronary infusion of BM-MC

    Bone marrow-derived progenitor autologous cells aspiration and intracoronary infusion of the cells.

    Procedure: Intracoronary infusion of BM-MC

Interventions

  • ProcedureIntracoronary infusion of BM-MC

    Bone marrow-derived progenitor cells are obtained from 60ml bone marrow aspirated from the iliac crest. Intracoronary infusion of the autologous cells is performed via conventional percutaneous intracoronary intervention techniques using an over-the-wire balloon technique.

06

What researchers measure

Primary outcomes

  1. Left ventricle ejection fraction change evaluated by CT

    Time frame: 12 months

Secondary outcomes

  1. Change in left ventricle End-Systolic Volume (ESV) and End-Diastolic Volume (EDV) evaluated by CT

    Time frame: 12 months

  2. Time from randomisation to cardiac death

    Time frame: 3 years

  3. Time from randomisation to cardiovascular death or rehospitalisation due to heart failure

    Time frame: 3 years

  4. Incidence and severity of adverse events

    Time frame: 3 years

07

Study locations

1 site
  • Polsko-Amerykańskie Kliniki Serca
    Ustroń, 43-450, Poland
    • Pawel E Buszman, MD, PhD · Contactpbuszman@ka.onet.pl · (+48) 607358348
    • Stanislaw A Trznadel, MD · Contact(+48) 502035700
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2019; primary completion for Jul 2022, 40 months later.

Of 87 non-industry phase 3 interventional studies under Heart Failure, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 40 months is below that.

Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2014
First posted
Dec 23, 2014
StartEst.
Mar 2019
Primary completionEst.
Jul 2022
CompletionEst.
Dec 2022
Last update
Jan 23, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02323620
Lead sponsor
American Heart of Poland
Responsible party
Pawel Buszman (MD, PhD, American Heart of Poland) — Principal investigator
First posted
Dec 23, 2014
Start date
Mar 2019 (estimated)
Primary completion
Jul 2022 (estimated)
Completion
Dec 2022 (estimated)
Last update
Jan 23, 2019

Study contacts

Pawel E. Buszman, MD, PhD,
Contact
pbuszman@ka.onet.pl
(+48) 607358348
Stanislaw A. Trznadel, MD
Contact
strznadel@vp.pl
(+48) 502035700
Pawel E Buszman, MD, PhD
principal investigator · American Heart of Poland

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion